The Theme Code "ペプチド又は蛋白質技術" had 96 patent application filings in the most recent period (2023-01-01 to 2023-03-31). This is a significantly decreased of -737 filings (-88.5%) over 833 they had in the same period of the previous year (2022-01-01 to 2022-03-31).
The highest number of filings in 2016 with 4,813 cases, and their lowest number in 2022 with 3,165 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 20,057 cases in total) is 3,343, and the median is 3,684. The coefficient of variation (standard deviation/mean) is 0.4, and there have been big fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 3,343 patents |
Std Dev | 1,504 |
COV | 0.4 |
The number of filings has been decreasing for the last 3 years (2020 to 2023).
Year | Cases | YOY |
---|---|---|
2022 year | 3,165 cases | -14.60 % |
2021 year | 3,706 cases | +1.23 % |
2020 year | 3,661 cases | -21.67 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for ペプチド又は蛋白質技術[4H045] for the period of the last 10 years (2014-01-01 to 2024-11-30). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of ペプチド又は蛋白質技術, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of ペプチド又は蛋白質技術 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Patent landscaping is a visualization of the distribution of patent filings (application focus areas) for each technical keyword. Mountains and islands indicated by heatmap contours represent clusters of patent applications filed, and red areas on the heatmap indicate many patent filings relating to the keyword.
The patent landscape for ペプチド又は蛋白質技術 gives an intuitive understanding of what patent filings they have made and what technical position is to be established. By selecting filing year checkboxes and filtering, you can track their past filing trends (what technical area they have focused on).
By selecting applicant/patent holder checkboxes and filtering, you can visually grasp the technical areas of the filings for each applicant and the partnerships or alliances formed. Please use it as a guide for patent analysis and IP landscaping.
In addition, by visually representing the patent data in this manner, you can convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
In Patent Integration, you can check the specifics of a patent filing by clicking anywhere on the patent landscape screen. You can also quickly check the position of each applicant for each technical field by cross-referencing with other keywords and patent classifications. You can use it as a guide when considering hypotheses about each company's IP strategy on the IP Landscape. You can also use it for higher-grade intellectual property activities. It has reasonable pricing and a simple user interface that is easy for beginners to handle.
The following is a list of words (characteristic terms) often used in ペプチド又は蛋白質技術 patent applications. Characteristic terms with a higher importance are used in more patents/patent applications.
This patent analysis report was created for a patent search set of 37,717 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The patent information of the higher applicant in the technical theme ペプチド又は蛋白質技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
Comparing the number of applications of each company, リジェネロン・ファーマシューティカルズ・インコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 56 cases, followed by ジェネンテックインコーポレイテッド with 37 cases.
Name | Cases |
---|---|
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 56 cases |
ジェネンテックインコーポレイテッド | 37 cases |
中外製薬株式会社 | 29 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 22 cases |
アムジエン・インコーポレーテツド | 22 cases |
エフホフマン-ラロシュアーゲー | 20 cases |
ノバルティスアーゲー | 18 cases |
国立研究開発法人産業技術総合研究所 | 10 cases |
武田薬品工業株式会社 | 5 cases |
Comparing the number of applications of each company, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 670 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 618 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 670 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 618 cases |
ノバルティスアーゲー | 509 cases |
エフホフマン-ラロシュアーゲー | 385 cases |
中外製薬株式会社 | 364 cases |
アムジエン・インコーポレーテツド | 288 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 286 cases |
武田薬品工業株式会社 | 153 cases |
国立研究開発法人産業技術総合研究所 | 95 cases |
味の素株式会社 | 67 cases |
国立研究開発法人科学技術振興機構 | 9 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The patent information of the higher applicant in the technical theme ペプチド又は蛋白質技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
among the top coapplicants, リジェネロン・ファーマシューティカルズ・インコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 56 cases, followed by ジェネンテックインコーポレイテッド with 37 cases.
Name | Cases |
---|---|
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 56 cases |
ジェネンテックインコーポレイテッド | 37 cases |
中外製薬株式会社 | 29 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 22 cases |
エフホフマン-ラロシュアーゲー | 20 cases |
ノバルティスアーゲー | 18 cases |
武田薬品工業株式会社 | 5 cases |
among the top coapplicants, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 670 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 618 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 670 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 618 cases |
ノバルティスアーゲー | 509 cases |
エフホフマン-ラロシュアーゲー | 385 cases |
中外製薬株式会社 | 364 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 286 cases |
武田薬品工業株式会社 | 153 cases |
Below is a ranking of the number of JP patent applications by ペプチド又は蛋白質技術’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by ペプチド又は蛋白質技術’s top 7 coapplicants over the last 20 years.
ペプチド又は蛋白質技術 filed 670 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 226 cases in total) is 37.7, and the median is 41.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 130 cases, and their lowest number in 2022 with 37 cases.
Index | Value |
---|---|
Average | 37.7 patents |
Std Dev | 18.3 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 37 cases | -24.49 % |
2021 year | 49 cases | +32.4 % |
2020 year | 37 cases | -17.78 % |
ペプチド又は蛋白質技術 filed 509 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 222 cases in total) is 37.0, and the median is 36.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 92 cases, and their lowest number in 2022 with 18 cases.
Index | Value |
---|---|
Average | 37.0 patents |
Std Dev | 23.7 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 18 cases | -50.0 % |
2021 year | 36 cases | -2.70 % |
2020 year | 37 cases | -41.3 % |
ペプチド又は蛋白質技術 filed 153 joint applications with 武田薬品工業株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 86 cases in total) is 14.3, and the median is 17.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2018 with 24 cases, and their lowest number in 2022 with 5 cases.
Index | Value |
---|---|
Average | 14.3 patents |
Std Dev | 8.8 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 5 cases | -68.8 % |
2021 year | 16 cases | -15.79 % |
2020 year | 19 cases | -13.64 % |
ペプチド又は蛋白質技術 filed 364 joint applications with 中外製薬株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 182 cases in total) is 30.3, and the median is 27.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2016 with 61 cases, and their lowest number in 2021 with 18 cases.
Index | Value |
---|---|
Average | 30.3 patents |
Std Dev | 17.8 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 24 cases | +33.3 % |
2021 year | 18 cases | -41.9 % |
2020 year | 31 cases | -35.4 % |
ペプチド又は蛋白質技術 filed 385 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 175 cases in total) is 29.2, and the median is 25.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 63 cases, and their lowest number in 2022 with 20 cases.
Index | Value |
---|---|
Average | 29.2 patents |
Std Dev | 18.7 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 20 cases | -4.76 % |
2021 year | 21 cases | -27.59 % |
2020 year | 29 cases | -42.0 % |
The following shows JP patents held by ペプチド又は蛋白質技術 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and ペプチド又は蛋白質技術’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which ペプチド又は蛋白質技術 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 5 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.0 times. The most recently Invalidation Trial patent is 特許7016341 "PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法" (Invalidation Trial day 2023-03-27) , next is 特許7083802 "グリコシル化された免疫グロブリンの調製方法" (Invalidation Trial day 2023-02-22) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許7016341 | PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法 | 2023-03-27 |
2 | 特許7083802 | グリコシル化された免疫グロブリンの調製方法 | 2023-02-22 |
3 | 特許6896700 | ワクチン組成物 | 2023-01-27 |
4 | 特許6278598 | 細胞傷害誘導治療剤 | 2022-03-31 |
5 | 特許6773929 | 細胞傷害誘導治療剤 | 2022-03-31 |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 7 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.3. The most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質" (2 times) , and the next most invalidation trial patent is 特許6198346 "1回当たり100〜200単位のPTHが週1回投与されることを特徴とする、PTH含有骨粗鬆症治療/予防剤" (2 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質 | 2 times |
2 | 特許6198346 | 1回当たり100〜200単位のPTHが週1回投与されることを特徴とする、PTH含有骨粗鬆症治療/予防剤 | 2 times |
3 | 特許6335326 | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用 | 1 times |
4 | 特許6896700 | ワクチン組成物 | 1 times |
5 | 特許6074462 | 抗−TNFα抗体の投与方法 | 1 times |
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 17 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7425092 "抗線維化剤、及び抗線維化作用を有する細胞外小胞の製造方法" (Opposition day 2024-07-29) , next is 特許7364841 "酸ハロゲン化物による化合物の製造方法" (Opposition day 2024-04-18) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7425092 | 抗線維化剤、及び抗線維化作用を有する細胞外小胞の製造方法 | 2024-07-29 |
2 | 特許7364841 | 酸ハロゲン化物による化合物の製造方法 | 2024-04-18 |
3 | 特許7328390 | フィブロイン様タンパク質の製造法 | 2024-02-15 |
4 | 特許7270912 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 | 2023-11-13 |
5 | 特許7257112 | 低分子量絹組成物および絹組成物の安定化 | 2023-10-12 |
6 | 特許7232758 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ | 2023-09-05 |
7 | 特許7222347 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | 2023-08-11 |
8 | 特許7168454 | 固体表面のスパイダーシルクコーティング | 2023-05-08 |
9 | 特許7162853 | 液相ペプチド合成用担体結合ペプチドの分析方法 | 2023-04-28 |
10 | 特許7117824 | モノクローナル抗体、検出方法、及び検出装置 | 2023-02-14 |
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 49 patents Protest from third parties. The average number of Protest is 1.3 times. The most recently Protest patent is 特開2023-052910 "可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩" (Protest day 2024-11-26) , next is 特表2021-522805 "hMPCの集団をゼノフリー生成するための方法" (Protest day 2024-11-08) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特開2023-052910 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | 2024-11-26 |
2 | 特表2021-522805 | hMPCの集団をゼノフリー生成するための方法 | 2024-11-08 |
3 | 特開2023-005522 | 浸透圧調節剤 | 2024-11-05 |
4 | 特表2023-534164 | 高多孔性スパイダーシルク繊維 | 2024-09-13 |
5 | 特表2022-546587 | 生物製剤の捕捉及び精製のための方法 | 2024-08-22 |
6 | 再公表2019/240288 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | 2024-08-08 |
7 | 特開2024-012433 | タンパク質成形体の製造方法、タンパク質溶液の製造方法及びタンパク質の製造方法 | 2024-06-14 |
8 | 特開2021-116244 | 高純度プロタミン硫酸塩 | 2024-05-29 |
9 | 特開2023-153171 | タンパク質成形体及びその製造方法、タンパク質溶液、並びにタンパク質成形体用可塑剤 | 2024-05-17 |
10 | 特表2022-513628 | クモ糸タンパク質のアルカリ精製法 | 2024-04-25 |
11 | 特表2021-534277 | 成形体用組成物 | 2024-04-25 |
12 | 特表2022-552052 | 抗VEGFタンパク質組成物及びその製造方法 | 2024-03-12 |
13 | 特表2023-525856 | ATI消化のための方法及び組成物 | 2024-02-28 |
14 | 特表2022-546204 | 苦味受容体ブロッカー及びその同定方法 | 2024-02-22 |
15 | 特開2023-052694 | 悪臭調節化合物の同定方法 | 2024-02-17 |
16 | 特表2021-506842 | ポリペプチドの放射性標識 | 2024-01-31 |
17 | 特開2023-052609 | 細胞培養物の製造方法 | 2024-01-23 |
18 | 特許7550225 | 溶液工程でのPNAオリゴマーの製造方法 | 2024-01-19 |
19 | 特開2021-095350 | 繊維芽細胞増殖促進用組成物、皮膚コラーゲン産生促進用組成物、皮膚ヒアルロン酸産生促進用組成物、皮膚エラスチン産生促進用組成物、及び保湿性の改善用組成物 | 2024-01-17 |
20 | 特表2022-548197 | 抗VEGFタンパク質組成物及びその製造方法 | 2024-01-15 |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 113 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.4. The most protest patent is 特開2017-061467 "血管新生眼疾患を処置するためのVEGFアンタゴニストの使用" (5 times) , and the next most protest patent is 特許6616332 "マイコプラズマ・ニューモニエの免疫学的検出法及びキット" (5 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2017-061467 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 5 times |
2 | 特許6616332 | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | 5 times |
3 | 特許7236796 | 風味が改善された脱脂植物蛋白およびその製造方法 | 4 times |
4 | 特開2019-167366 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 4 times |
5 | 特許6616333 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 4 times |
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 572 patents Inspection from third parties. The average number of Inspection is 1.2 times. The most recently Inspection patent is 特表2022-547154 "調節可能な制御のためのCA2-IL15融合タンパク質" (Inspection day 2024-11-25) , next is 特表2021-522805 "hMPCの集団をゼノフリー生成するための方法" (Inspection day 2024-11-25) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特表2022-547154 | 調節可能な制御のためのCA2-IL15融合タンパク質 | 2024-11-25 |
2 | 特表2021-522805 | hMPCの集団をゼノフリー生成するための方法 | 2024-11-25 |
3 | 特表2022-516318 | カプセル化ポリヌクレオチド及び使用方法 | 2024-11-22 |
4 | 特表2022-516199 | ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物 | 2024-11-21 |
5 | 特表2022-514116 | 新規な癌抗原及び方法 | 2024-11-21 |
6 | 特許6231007 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
7 | 特許7250736 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
8 | 特許7194240 | 抗BCMA抗体、BCMA及びCD3に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
9 | 特許6378087 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
10 | 特開2017-195889 | BCMAおよびCD3に対する結合分子 | 2024-11-15 |
11 | 特開2023-027228 | 抗BCMA抗体、BCMA及びCD3に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
12 | 特表2018-525005 | 抗BCMA抗体、BCMA及びCD3に結合する二重特異性抗原結合分子、並びにそれらの使用 | 2024-11-15 |
13 | 特表2022-518223 | 不妊治療成功の予測のための子宮内膜液 | 2024-11-13 |
14 | 特開2024-149479 | 黄熱を処置するための方法および組成物 | 2024-11-11 |
15 | 特開2023-005522 | 浸透圧調節剤 | 2024-11-07 |
16 | 特開2022-137094 | グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 | 2024-11-07 |
17 | 特表2022-545835 | 甲状腺眼症の治療方法 | 2024-11-07 |
18 | 特表2023-504773 | 眼遺伝子送達のためのAAVベクター変異体 | 2024-11-07 |
19 | 特表2022-504139 | バイオフィルムの除去のためのHMGB1タンパク質誘導体 | 2024-11-05 |
20 | 特表2022-516574 | 新規ペプチドとその使用 | 2024-11-05 |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 1,097 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.2. The most inspection patent is 特許6198346 "1回当たり100〜200単位のPTHが週1回投与されることを特徴とする、PTH含有骨粗鬆症治療/予防剤" (18 times) , and the next most inspection patent is 特開2019-167366 "血管新生眼疾患を処置するためのVEGFアンタゴニストの使用" (10 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6198346 | 1回当たり100〜200単位のPTHが週1回投与されることを特徴とする、PTH含有骨粗鬆症治療/予防剤 | 18 times |
2 | 特開2019-167366 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 10 times |
3 | 特許6616332 | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | 9 times |
4 | 特許6616333 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 9 times |
5 | 特許7117824 | モノクローナル抗体、検出方法、及び検出装置 | 8 times |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 4,427 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.2. The most cited patent is 特許6232009 "CDRのアミノ酸置換により抗体の等電点を改変する方法" (40 times) , and the next most cited patent is 特許6196343 "免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド" (36 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6232009 | CDRのアミノ酸置換により抗体の等電点を改変する方法 | 40 times |
2 | 特許6196343 | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド | 36 times |
3 | 特許6082447 | 複数分子の抗原に繰り返し結合する抗原結合分子 | 34 times |
4 | 特許6400738 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 | 33 times |
5 | 特表2017-500035 | 遺伝子編集用のCAS多様体 | 29 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International